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ABSTRACT 
Recently, serumal surfactant protein D (SP-D) has been 
shown to correlate with the development of dementia. 
As SP-D can be measured reliably in saliva, this might 
provide opportunities for a non-invasive biomarker. This 
preliminary study aims to determine a possible 
difference between the levels of salivary SP-D in non-
demented elderly and late stage demented elderly. 
Results indicate a significant difference between 
demented subjects and controls, and between male and 
female demented subjects. This suggests SP-D could be 
used as a biomarker to improve detection of dementia. 
Further research should focus on early-stage dementia 
and the role of innate immunity in dementia. 
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INTRODUCTION 
In the search for a cure for dementia, it is of major 
importance to be able to detect this disorder in an early 
stage. Biomarkers could be especially important in 
clarifying the underlying pathophysiologies of dementia, 
such as Alzheimer’s disease, and could eventually lead 
to improved diagnostic tools and treatment options 
(DeKosky & Marek, 2003). This search for new, 
improved biomarkers is an ongoing process. An example 
of a recently proposed biomarker for dementia is 
surfactant protein D (SP-D) (Nybo et al., 2007). 
 
SP-D and innate immunity   
SP-D is a surfactant protein and is a member of the 
collectin-family. It is primarily known for its pulmonary 
function and, as such, is involved in the host defence 
response and the clearance of apoptotic cells (Vandivier 
et al., 2002). In addition, SP-D knock-out mice showed 
increased aggregation of alveolar macrophages and a 
disturbed lipoprotein homeostasis (Botas et al., 1998). 
Interestingly, Schob and colleagues (2013) recently 
reported that SP-D was expressed in the brain of adult 
rats, specifically in the blood-brain barrier, choroid 
plexus, and superficial glia limitans. This, together with 
the fact that surfactant proteins regulate inflammatory 
responses and help clear apoptotic cells, suggest that 
these proteins play a role in the innate immune system of 
the brain and cerebrospinal fluid (Schob et al., 2017). 
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Innate immunity and dementia  
Recent research (Heneka, Golenbock, & Latz, 2015) has 
suggested neuroinflammation plays an important role in 
Alzheimer’s disease’s pathology. In general, the 
formation of beta-amyloid (Aβ) peptides is seen as the 
first (detectable) step in the development of dementia. 
This aggregation of Aβ could lead to chronic activation 
of the immune system. In turn, the immune system 
causes a disturbance in microglial functioning, 
especially with regards to clearance of apoptotic cells. In 
addition, Alzheimer’s disease (AD) was reported to 
correlate with extensive upregulation of genes involved 
in the innate immune system, possibly even in 
preclinical stages (Cribbs et al., 2012), supporting the 
notion that the immune system plays an important role in 
the development of dementia.   
SP-D and dementia  
Nybo and colleagues (2007) examined serumal SP-D 
levels of 418 non-demented participants at baseline and 
after three years of follow-up. At follow-up, 27 of the 
346 remaining participants showed signs of dementia. 
From the blood samples, it was concluded that higher 
serum SP-D levels correlated with an increased risk of 
developing dementia, with a risk ratio of 2.62. A strong 
connection between the development of dementia and 
inflammatory reactions has been suggested. As SP-D is 
known to play a role in the innate immune system, the 
finding that SP-D is correlated with the development of 
dementia could provide new insights in the underlying 
pathophysiology and could even lead to a new biomarker 
to detect dementia in an early stage.   
Ideally, biomarkers to detect dementia would be 
inexpensive, easily collected and analysed, and 
minimally invasive. As SP-D has been shown to be 
present in saliva (Bräuer et al., 2009), the use of salivary 
SP-D would be preferred over the use of serum SP-D. 
Nevertheless, no research has looked into the correlation 
between salivary SP-D levels and dementia yet. Hence, 
this study will determine if there are differences in 
salivary SP-D levels between moderately to severely 
demented elderly and non-demented elderly, using a 
Luminex multiplex immunoassay. Samples were taken 
in the morning and the evening, to see if there is a 
possible diurnal rhythm in the presence of SP-D, which 
could influence the efficacy of the possible biomarker. If 
SP-D is indeed shown to correlate with dementia, this 
could be a step forward in the development of non-
invasive detection methods for dementia.  
 
METHODS 
Participants  
All participants in this study were part of a larger study 
concerning the effects of bright light therapy (BLT) on 
moderately to severely demented elderly in nursing  
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	homes. All participants were nursing home residents and 
were under constant care. In this sub-study, saliva 
samples from 58 participants, grouped for three different 
time periods, in both the morning (O1, O3, O5) and the 
evening (A1, A3, A5), were included. Informed consent, 
either self-provided or provided by relatives, was 
obtained for all participants. Table 1 shows demographic 
details of all participants.  
 
Table 1 – Demographic details of all participants 
 Demented elderly Controls 
Gender (count) female 33 11 
male 21 6 
Diagnosis 
(count) 
Alzheimer 19  
Vascular 4  
Mixed 11  
Other 20  
Age (years) Mean 85.87 79.29 
St. Dev. 7.24 8.01 
Sample collection  
Samples were obtained using Salivette® cotton swabs 
prior to ingesting food, non-water drinks, and 
medication, and before brushing of the teeth in the 
morning (07:00 – 09:00), and an hour after dinner, 
before drinking coffee, in the evening (19:00 – 21:00). 
After collection, samples were refrigerated until 
centrifugation, followed by aliquoting samples into Cryo 
cups,  and were subsequently frozen at -18˚C until use. 
For the comparisons between the experimental 
(demented) and control group (non-demented), samples 
from O1 were used.  
Luminex multiplex immunoassay  
SP-D levels were determined using a Human Premixed 
Multi-Analyte Kit (CHI3-L1&SP-D), cat. LXSAHM-2, 
lot 1363794 from R&D Systems. At an earlier time 
point, two plates were measured, containing an eight-
point three fold standard curve, two blanks, samples 
from the control group, and 88 experimental samples in 
total. Three  additional plates were measured at a later 
time point, each containing 78 samples from the 
experimental group as well as standard dilutions. In 
order to verify consistency between these two 
measurements, ten experimental samples measured at the 
first time point repeated at the second time point.   
The antibody mixture used in this experiment was 
provided and verified for SP-D by R&D systems. To 
perform the experiment, eight three-fold standard 
dilutions were made, from which standard curves were 
generated. The wells for the standard curve contained 50 
µL of the standard dilutions and 50 µL of the bead 
solution. Wells with samples contained 25 µL of saliva, 
25 µL of calibrator diluent (as provided by R&D 
systems), and 50 µL of bead solution. Eight samples did 
not contain sufficient saliva and were diluted more, 
which was corrected for in the calculations.  
After adding the bead solution to the wells, the plates 
were incubated for two hours and subsequently washed 
three times. Afterwards, 50 µL of detection antibody 
solution was added and the plates were incubated for 
another hour. The washing step was repeated and 50 µL 
streptavidin PE solution was added as a reporter protein. 
After incubation of 30 minutes, the plates were washed 
and samples were suspended in 100 µL washing buffer. 
The plates were incubated for two minutes and analysed 
using a Bioplex reader. The Bioplex reader measured the 
beads using two laser beams of different frequencies, the 
first of which identifies the bead’s colour to classify the 
analyte. The second laser determines the fluorescence of 
the bead, which is an indicator of the amount of bound 
streptavidin PE, and thus of SP-D present on the bead. 
The needed time per sample was approximately thirty 
seconds.  
Data analysis 
Before statistical analysis, as per convention, samples 
registering as out of range on the lower bound were  
assigned half of the lowest measured value, as not to 
lose data. Additionally, the measured values were  
converted into their base ten logarithm, in order to 
reduce variance in the data.  
Using a Shapiro-Wilk test, the normality of the sample 
was assessed. For the control group (p=.002) and most 
of the experimental categories (O1: p=.101, A1: p=.000, 
O3: p=.000, A3: p=.000, O5: p=.287 , and A5: p=.001) 
the null-hypothesis was rejected and therefore normality 
cannot be assumed for any data. Thus, these data were 
analysed using nonparametric tests. 
First, background checks were  performed. Two sets of 
samples were measured at two different time points, 
differing about a year. Control samples were only 
measured at the earlier time point. To check for sample 
and assay degradation, some previously measured 
samples (n=10) were assayed again. Subsequently, their 
data were compared using a Wilcoxon signed-rank test. 
In order to rule out differences in age and sex between 
the control group and experimental group as 
confounding factors,  a Mann-Whitney U test and a 
Pearson’s χ2-test were used, respectively.  
To assess the main research question and sex differences 
in the logarithm of the observed concentrations, Mann-
Whitney U tests were used to identify significant 
differences in means. A Wilcoxon signed-rank test was 
used to identify a possible diurnal rhythm of SP-D. A 
Kruskal-Wallis H test was used to assess the differences 
in SP-D concentration across the different diagnoses 
(Table 1). Lastly, to assess the relationship between SP-
D concentration and age, a bivariate analysis using 
Pearson’s r was used. 
 
RESULTS  
Background checks  
The earliest measured samples (M=2.0504, SD=.6303) 
were significantly different (Z=-2.599, p=.006) from 
samples measured  at the later time point (M=2.3342, 
SD=.3116). The gender distribution did not differ by 
experimental condition, χ2(1, N=71)=.071, p=.790. A 
Mann-Whitney U  tests showed that there was a 
significant difference in age between the experimental 
(M=85.87, SD=7.237) and control group (M=79.29, 
SD=8.006), (Z=-2.996, p=.003). 
Controls versus dementia patients 
Concerning the main research question, a Mann-
Whitney U test showed there is a large, and highly 
significant difference between the logarithm of the 
observed SP-D concentration in the experimental 
(M=2.3883, SD=.6641) and control group (M=1.2037, 
SD=.6975), (Z=-4.530, p=.000), see Figure 1. 
 
	Age and SP-D  
There was no significant correlation between age and 
SP-D in the experimental group, r(54)=.158, p=.255, nor 
in the control group, r(17)=.385, p=.127.  
Sex and SP-D  
A Mann-Whitney U test showed a significant difference 
between male and female subjects in the logarithm of the 
observed SP-D concentration for the experimental group 
(Mf=2.5703, SDf=.5867, Mm=2.1023, SDm=.6910), (Z=-
2.342, p=.019). However, the control group did not 
show a significant sex difference (Mf=1.1921, 
SDf=.8687, Mm=1.2249, SDm=.9544), (Z=-.208, p=.884), 
see Figure 1. This suggests an effect of sex on  salivary 
SP-D levels in dementia patients, but not in the non-
demented elderly. However, the small size of the control 
group might explain the lack of significance.  
	
Figure 1 - Logarithm of observed concentration of SP-D in non-
demented and demented elderly; overall averages and by sex. This graph 
illustrates the significant differences between demented and non-
demented elderly (p=.000), and  between males and females in  demented 
elderly (p=.019)  as opposed to in non-demented elderly (p=.884). 
Diagnosis and SP-D  
There was no significant difference between the 
logarithm of the observed concentration for patients with 
different diagnoses (H(3)=2.128, p=.546), with a mean 
rank of 24.9 for Alzheimer’s Disease, 20.5 for vascular 
dementia, 29.3 for mixed diagnoses, and 30.4 for 
undefined diagnoses,  suggesting that diagnosis and SP-
D levels in demented elderly do not correlate. 
Diurnal rhythm and SP-D 
Wilcoxon signed-rank tests showed that there is a 
significant difference in the logarithm of the SP-D 
concentration between morning and evening samples for 
day one and three (Z=-3.405, p=.001; Z=-2.669, 
p=.007), but not for day five (Z=-1.599, p=.113).  These 
data, especially in combination with the similarity of the 
differences in means (ΔM1=.26, ΔM3=.23, ΔM5=.21), 
suggest a probable diurnal rhythm for SP-D in elderly 
with dementia. The lack of significance on day five 
could be explained by the smaller sample size as an 
effect of higher mortality. 
 
DISCUSSION & CONCLUSION 
The fact that the differences between SP-D 
concentrations in controls and dementia patients were 
significant suggests that salivary SP-D concentrations are 
higher in dementia patients. This supports the hypothesis 
that SP-D plays a role in dementia, even though the 
mechanism behind it is still unknown. Part of this effect 
might be explained by the significant difference between 
the sample sets measured at the different time points, as 
the control samples were all measured at the earlier time 
point and on one plate. However, the difference between 
the two repeated measurements (ΔM=.2383) is much 
smaller than the difference between the control and 
experimental groups (ΔM=1.1846). This suggests that 
there is still a difference in SP-D concentration between 
non-demented and demented elderly, yet the results 
should be treated with caution. Additionally, the 
significant difference between morning and evening 
samples indicates the presence of a diurnal rhythm for 
SP-D. Lastly, the significant difference in SP-D 
concentrations between the sexes in demented elderly 
could point at  possibly sex-specific underlying 
mechanisms of SP-D. Due to small sample size, 
however, this effect could not be verified in control 
subjects. 
The higher SP-D concentration in dementia patients 
could be an indicator of an innate immune system 
response to a chronic inflammatory reaction in the brain 
(Heneka et al., 2015). SP-D has been shown to have both 
pro- and anti-inflammatory properties (Gardai et al., 
2003), so it could either enhance this reaction, or reduce 
it by enhancing clearance of apoptotic cells. This 
clearance might be disturbed in the brain of dementia 
patients and thus contribute to the development of 
dementia (Kao et al., 2011). In addition, SP-D might be 
associated with microglia, which have similar clearance 
functions in the innate immune system (Heneka et al., 
2015). Therefore, further research should try to clarify 
the exact relationships between SP-D, the innate immune 
system, and the development of dementia.  
These results support the suggestion that SP-D is a good 
candidate for a biomarker for dementia detection, as well 
as a subject for future research into the 
pathophysiologies underlying dementia. The fact that 
there were no significant differences in concentration 
across the diagnoses suggests SP-D could detect 
multiple types of dementia, however not distinguish 
between these,  and could thus be used in a wide variety 
of clinical and research settings. A simple saliva 
collection procedure could, in the future,  possibly 
become part of a swifter and safer diagnosis process 
without an immediate need for neuropsychological 
testing.  
As our preliminary study was part of a bigger study, the 
experimental group consisted mostly of moderately to 
severely demented elderly. This means this study can be 
used as a proof of principle, but that to adequately assess 
the use of SP-D as a biomarker for dementia, future 
studies should focus on mildly demented subjects or on 
birth cohorts of risk-populations. The sample sizes in 
this study, specifically for the control group,  were 
relatively small, suggesting that the results might not be 
generalisable to the entire population. In addition, there 
was a significant difference in age between the control 
and experimental group, which should, however, not 
affect this study’s conclusions, as age was not 
significantly correlated with SP-D concentration. 
Furthermore, the samples were not all measured at the 
same time, which led to a significant difference between 
the observed concentrations measured at different time 
points, yet as described above, this should not change 
the main conclusions of this study. Lastly, many values 
were out of range at the lower bound and could therefore 
not be determined exactly. This was corrected for by 
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	taking half of the lowest value, which might have 
affected the exact findings of this studies, but most likely 
not its conclusions.  
To adequately assess the relationship between SP-D and 
dementia, future studies should use larger sample groups 
and age-matched controls. Such a bigger study should 
include a wide range of subjects with several types of 
dementia. Only such a study could appropriately verify 
if there are indeed no significant differences in SP-D 
concentrations across the diagnoses, and if there is no 
sex difference in non-demented elderly. Additionally, 
such a study could also analyse the concentration 
differences separately for both sexes in order to rule out 
a sex-effect, where SP-D would be a reliable biomarker 
in one sex, but not the other. Secondly, a cohort study in 
elderly, or a population-wide study, is recommended to 
appropriately assess the use of SP-D as a biomarker and 
predictor for dementia, as well as to identify effects of 
covariants, such as age and sex, on SP-D levels across 
all ages. Such a study could also determine if SP-D 
could be used to differentiate between other 
neurodegenerative disorders, such as Parkinson’s 
disease, and the several types of dementia. Lastly, as SP-
D levels were found to be relatively low, it is 
recommended to use a more sensitive detection method 
to determine these concentrations of SP-D, or 
alternatively, repeat measurements of out of range values 
with a doubled sample volume.  
In conclusion, this preliminary study serves as a proof of 
principle that salivary SP-D is a promising candidate to 
serve as a biomarker for detection of dementia and could 
provide new insights the underlying pathophysiology of 
dementia. To confirm these findings and to identify the 
exact relationship between dementia, SP-D, age and sex, 
future research is needed. 
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